The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound helps aid weight loss. Research consistently suggests people with overweight or obesity have more average weight loss on Zepbound than a placebo. The active ingredient in Zepbound is ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

The Food and Drug Administration ... drug should be combined with a reduced-calorie diet and increased physical activity. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed ...

The Food and Drug Administration ... giving the stamp of approval for Zepbound's use among adults with obesity for use in combination with a reduced-calorie diet and increased physical activity.

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration ... with a reduced-calorie diet and increased physical activity.

The Food and Drug Administration ... Demand for Zepbound and Mounjaro has been so hot that Eli Lilly has struggled to make enough, leading the FDA to place it on a list of drugs in shortage ...